Histopathological changes and tumour necrosis factor-α, transforming growth factor-β and tenascin expression in patients with primary type i membranoproliferative glomerulonephritis in remission

Nephrology

Volumn 14, Issue 2, 2009, Pages 219-226

  Arikan, Hakki ^a,b   Koc, Mehmet ^b   Cakalagaoglu, Fulya ^c   Tuglular, Serhan ^b   Ozener, Cetin ^b   Akoglu, Emel ^b  

^a MARMARA UNIVERSITY   (Turkey)

^b Division of Nephrology   (Turkey)

^c MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Histopathology; Primary membranoproliferative glomerulonephritis; Re biopsy; Relapse; Tenascin

Indexed keywords

TENASCIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; LABORATORY TEST; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MESANGIUM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELAPSE; REMISSION;

ADULT; BIOPSY; FEMALE; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; KIDNEY; MALE; MIDDLE AGED; TENASCIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 63849106938     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2008.01048.x     Document Type: Article

References (34)

1. Falk JR, Jennette JC, Nachman PH. Primary glomerular disease. In : Brenner BM (ed.). Brenner & Rector's The Kidney, 7th edn. Philadelphia, Pennsylvania : Saunders, 2004 1293 80.
2. D'Amico G, Ferrario F. Mesangiocapillary glomerulonephritis. J. Am. Soc. Nephrol. 1992 2 (Suppl 10 159 66.
3. Cameron JS, Turner DR, Heaton J et al. Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. Am. J. Med. 1983 74 : 175 92.
4. McEnery PT. Membranoproliferative glomerulonephritis: The Cincinnati experience-cumulative renal survival from 1957 to 1989. J. Pediatr. 1990 116 : 109 14.
5. Bergstein JM, Andreoli SP. Response of type I membranoproliferative glomerulonephritis to pulse methylprednisolone and alternate-day prednisone therapy. Pediatr. Nephrol. 1995 9 : 268 71.
6. Zauner I, Bohler J, Braun N, Grupp C, Heering P, Schollmeyer P. Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis: A multicentre prospective clinical trial. Collaborative Glomerulonephritis Therapy Study Group (CGTS). Nephrol. Dial. Transplant. 1994 9 : 619 22.
7. Donadio JV Jr., Offord KP. Reassessment of treatment results in membranoproliferative glomerulonephritis, with emphasis on life-table analysis. Am. J. Kidney Dis. 1989 14 : 445 51.
8. Faedda R, Satta A, Tanda F, Pirisi M, Bartoli E. Immunosuppressive treatment of membranoproliferative glomerulonephritis. Nephron 1994 67 : 59 65.
9. Toz H, Ok E, Unsal A, Asci G, Basdemir G, Basci A. Effectiveness of pulse cyclophosphamide plus oral steroid therapy in idiopathic membranoproliferative glomerulonephritis. Nephrol. Dial. Transplant. 1997 12 : 1081 2.
10. Gomez-Guerrero C, Lopez-Armada MJ, Gonzalez E, Egido J. Soluble IgA and IgG aggregates are catabolized by cultured rat mesangial cells and induce production of TNF-alpha and IL-6, and proliferation. J. Immunol. 1994 153 : 5247 5.
11. Neale TJ, Ruger BM, Macaulay H et al. Tumor necrosis factor-alpha is expressed by glomerular visceral epithelial cells in human membranous nephropathy. Am. J. Pathol. 1995 146 : 1444 54.
12. Kitamura M, Burton S, English J, Kawachi H, Fine LG. Transfer of a mutated gene encoding active transforming growth factor-beta 1 suppresses mitogenesis and IL-1 response in the glomerulus. Kidney Int. 1995 48 : 1747 57.
13. Border WA, Noble NA, Yamamoto T et al. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 1992 360 : 361 4.
14. Yamamoto T, Noble NA, Miller DE, Border WA. Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis. Kidney Int. 1994 45 : 916 27.
15. Okada M, Takemura T, Murakami K, Hino S, Yoshioka K. Expression of tenascin in normal and diseased human kidneys. Nippon Jinzo Gakkai Shi 1996 38 : 213.
16. Truong LD, Foster SV, Barrios R et al. Tenascin is an ubiquitous extracellular matrix protein of human renal interstitium in normal and pathologic conditions. Nephron 1996 72 : 579 86.
17. Danilewicz M, Wagrowska-Danilewicz M. Morphometric comparison of the quantity of the mesangial deposits in rebiopsied patients with idiopathic mesangial proliferative glomerulonephritis. Pathol. Res. Pract. 2001 197 : 545 50.
18. Danilewicz M, Wagrowska-Danilewicz M. Immunohistochemical analysis of the interstitial mast cells in rebiopsied patients with idiopathic mesangial proliferative glomerulonephritis. Pol. J. Pathol. 2005 56 : 63 8.
19. Donadio JV, Bergstralh EJ, Offord KP, Holley KE, Spencer DC. Clinical and histopathologic associations with impaired renal function in IgA nephropathy. Mayo Nephrology Collaborative Group. Clin. Nephrol. 1994 41 : 65 71.
20. Inaba S, Tanizawa T, Takahashi T et al. Decrease of mesangial matrix after immunosuppressive therapy in children with reversible membranoproliferative glomerulonephritis type I. Clin. Nephrol. 1996 45 : 217 25.
21. Wagrowska-Danilewicz M, Danilewicz M. Evaluation of clinical and morphologic changes in mesangiocapillary glomerulonephritis (MCGN) in reference to re-biopsy Abstract Przegl. Lek. 1994 51 : 175 8.
22. Danilewicz M, Wagrowska-Danilewicz M. Morphometric comparison of the quantity of the mesangial deposits in rebiopsied patients with idiopathic mesangial proliferative glomerulonephritis. Pathol Res Pract 2001 197 : 545 50.
23. Schocklmann HO, Lang S, Sterzel RB. Regulation of mesangial cell proliferation. Kidney Int. 1999 56 : 1199 207.
24. Truong LD, Pindur J, Barrios R et al. Tenascin is an important component of the glomerular extracellular matrix in normal and pathologic conditions. Kidney Int. 1994 45 : 201 10.
25. Truong LD, Majesky MW, Pindur J. Tenascin is synthesized and secreted by rat mesangial cells in culture and is present in extracellular matrix in human glomerular diseases. J. Am. Soc. Nephrol. 1994 4 : 1771 7.
26. Koukoulis GK, Gould VE, Bhattacharyya A, Gould JE, Howeedy AA, Virtanen I. Tenascin in normal, reactive, hyperplastic, and neoplastic tissues: Biologic and pathologic implications. Hum. Pathol. 1991 22 : 636 43.
27. Gould VE, Martinez-Lacabe V, Virtanen I, Sahlin KM, Schwartz MM. Differential distribution of tenascin and cellular fibronectins in acute and chronic renal allograft rejection. Lab. Invest. 1992 67 : 71 9.
28. Fukuda M, Morozumi K, Uchida K et al. Glomerular capillary tenascin staining in renal allografts and its correlation with capillary loop 'double contours', proteinuria and graft outcome. Nephron. Clin. Pract. 2004 96 : 115 22.
29. Masaki T, Yorioka N, Taniguchi Y, Oda H, Yamakido M. Tenascin expression may reflect the activity and chronicity of human IgA nephropathy. Clin. Nephrol. 1998 50 : 205 13.
30. Wagrowska-Danilewicz M, Danilewicz M. Immunohistochemical study of tenascin in mesangial proliferative (IgA-negative) glomerulonephritis. Acta. Histochem. 1999 10 : 351 9.
31. Onetti Muda A, Feriozzi S, Rahimi S, Faraggiana T. Expression of TGF-beta receptors type I and II in human glomerulonephritis. Nephrol. Dial. Transplant. 1998 13 : 279 84.
32. Nakamura A, Johns EJ, Imaizumi A, Niimi R, Yanagawa Y, Kohsaka T. Role of angiotensin II-induced cAMP in mesangial TNF-alpha production. Cytokine 2002 19 : 47 51.
33. Neale TJ, Ruger BM, Macaulay H et al. Tumor necrosis factor-alpha is expressed by glomerular visceral epithelial cells in human membranous nephropathy. Am. J. Pathol. 1995 146 : 1444 54.
34. Wuthrich RP, Glimcher LH, Yui MA, Jevnikar AM, Dumas SE, Kelley VE. MHC class II, antigen presentation and tumor necrosis factor in renal tubular epithelial cells. Kidney Int. 1990 37 : 783 92.